Incyte Price Target Cut to $67 by JPMorgan Analyst
ByAinvest
Monday, Jul 14, 2025 12:51 pm ET1min read
INCY--
Incyte, a Wilmington, Delaware-based biopharmaceutical company focused on innovative therapies in oncology, immunology, dermatology, and inflammation, is expected to report its Q2 2025 earnings on Tuesday, April 29. Prior to this event, analysts project the company to report a profit of $1.13 per share, up 155.7% from a loss of $2.03 per share in the year-ago quarter [1].
Incyte has seen a 13.2% increase in its stock price over the past 52 weeks, outpacing both the S&P 500 Index's 12.3% gain and the Health Care Select Sector SPDR Fund’s 6.5% decline over the same period [1]. The company's strong clinical trial results for an experimental therapy aimed at treating a blood disorder have bolstered investor confidence in its research pipeline [1].
Despite the positive developments, Incyte faces several challenges. The company has missed Wall Street's bottom-line estimates in three of the last four quarters, while surpassing on one quarter [1]. Additionally, the company's growth has been partially offset by a reduction in channel inventory, impacting net revenue growth [2].
Analysts are moderately optimistic about Incyte's stock, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, ten recommend a "Strong Buy," 14 advise "Hold," and one suggests a "Strong Sell" rating [1]. The mean price target of $76.09 indicates a 26.8% potential upside from Incyte’s current price levels [1].
Incyte's Q2 2025 earnings report is anticipated to provide further insights into the company's financial health and growth prospects. Investors will be closely watching the report for updates on the company's product revenue, cash position, and research and development expenses [2].
References:
[1] https://finance.yahoo.com/news/incyte-q2-2025-earnings-expect-125830294.html
[2] https://www.gurufocus.com/news/2974146/incyte-incy-price-target-adjusted-by-jpmorgan-incy-stock-news
JPM--
JPMorgan analyst Jessica Fye lowered Incyte's price target to $67 from $68 and maintains a Neutral rating on the shares. The firm adjusted its model ahead of the Q2 report.
JPMorgan analyst Jessica Fye has revised her price target for Incyte Corporation (INCY) from $68 to $67, maintaining a Neutral rating on the shares. This adjustment comes as the firm recalibrates its model in anticipation of Incyte's second-quarter financial results [2].Incyte, a Wilmington, Delaware-based biopharmaceutical company focused on innovative therapies in oncology, immunology, dermatology, and inflammation, is expected to report its Q2 2025 earnings on Tuesday, April 29. Prior to this event, analysts project the company to report a profit of $1.13 per share, up 155.7% from a loss of $2.03 per share in the year-ago quarter [1].
Incyte has seen a 13.2% increase in its stock price over the past 52 weeks, outpacing both the S&P 500 Index's 12.3% gain and the Health Care Select Sector SPDR Fund’s 6.5% decline over the same period [1]. The company's strong clinical trial results for an experimental therapy aimed at treating a blood disorder have bolstered investor confidence in its research pipeline [1].
Despite the positive developments, Incyte faces several challenges. The company has missed Wall Street's bottom-line estimates in three of the last four quarters, while surpassing on one quarter [1]. Additionally, the company's growth has been partially offset by a reduction in channel inventory, impacting net revenue growth [2].
Analysts are moderately optimistic about Incyte's stock, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, ten recommend a "Strong Buy," 14 advise "Hold," and one suggests a "Strong Sell" rating [1]. The mean price target of $76.09 indicates a 26.8% potential upside from Incyte’s current price levels [1].
Incyte's Q2 2025 earnings report is anticipated to provide further insights into the company's financial health and growth prospects. Investors will be closely watching the report for updates on the company's product revenue, cash position, and research and development expenses [2].
References:
[1] https://finance.yahoo.com/news/incyte-q2-2025-earnings-expect-125830294.html
[2] https://www.gurufocus.com/news/2974146/incyte-incy-price-target-adjusted-by-jpmorgan-incy-stock-news
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet